FIRST REAL-WORLD STUDY ASSESSING HEALTH UTILITY VALUES FOR CHRONIC SPONTANEOUS/IDIOPATHIC URTICARIA USING THE EQ-5D
Author(s)
McBride D1, Chambenoit O2, Chiva-Razavi S2, Lynde C3, Sussman G4, Chapman-Rothe N5, Weller K6, Maurer M6, Koenders J7, Knulst AC8, Elberink JN9, Halliday A10, Alexopoulos ST10, Nakonechna A11, Abouzakouk M11, Sweeney C12, Radder C12, Wolin D13, Hollis K12, Tian H14, Balp M15, Grattan C16
1RTI Health Solutions, Manchester, UK, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 3Lynderm Research Inc., Toronto, ON, Canada, 4St Michael's Hospital, University of Toronto, Toronto, ON, Canada, 5Novartis Pharma GmbH, Nuernberg, Germany, 6Charite - Universitätsmedizin Berlin, Berlin, Germany, 7Novartis Pharma B.V., Arnhem, The Netherlands, 8University Medical Center Utrecht, Utrecht, The Netherlands, 9Unviersity Medical Center Groningen, Groningen, The Netherlands, 10Novartis Pharmaceuticals UK Limited, Surrey, UK, 11Hull and East Yorkshire NHS Hospital Trust, Hull, UK, 12RTI Health Solutions, Research Triangle Park, NC, USA, 13RTI Health Solutions, Ann Arbor, MI, USA, 14Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 15Novartis Pharma AG, Basel, Switzerland, 16Norfolk and Norwich University Hospital, Norwich, UK
Conference/Value in Health Info
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PSS54
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities
Disease
Sensory System Disorders